Takeda is to withdraw Exkivity, its treatment for EGFR Exon20 insertion mutation-positive non-small cell lung cancer, from the US and other markets after it failed to show its value over standard chemotherapy in a Phase III confirmatory trial.
The oral tyrosine kinase inhibitor gained an accelerated US marketing approval in September 2021, based on Phase I/II trial results...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
